← All countries · Europe
85%
MCV1
2025 · WHO/UNICEF estimate
88%
DTP3
2025 · WHO/UNICEF estimate
88%
IPV complete
2025 · WHO/UNICEF estimate
88%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 0%2005 · Administrative (country-reported) | 0% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 89%2025 · WHO/UNICEF estimate | 89.4% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 88%2025 · WHO/UNICEF estimate | 88.0% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 89%2025 · WHO/UNICEF estimate | 88.9% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 88%2025 · WHO/UNICEF estimate | 87.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 85%2025 · WHO/UNICEF estimate | 85.1% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 85%2025 · WHO/UNICEF estimate | 85.0% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 85%2025 · WHO/UNICEF estimate | 85.1% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 88%2025 · WHO/UNICEF estimate | 88.0% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 100%2011 · Administrative (country-reported) | 100% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 88%2025 · WHO/UNICEF estimate | 87.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 82.7%2025 · Administrative (country-reported) | 82.7% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 81%2025 · WHO/UNICEF estimate | 80.8% | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2005 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | 12.2%2021 · Administrative (country-reported) | 12.2% | D · poor | |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 62%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 57%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 49%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (59 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| CHOLERACholera vaccine | 1 | Travellers | Travellers | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Older adults with chronic conditions | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M11 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y5 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Risk categories, outbreaks, travellers | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Travellers | Risk categories, outbreaks, travellers | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Risk categories, outbreaks, travellers | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Travellers | Risk categories, outbreaks, travellers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Risk categories (workers not yet covered by vaccination are also included) | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Administered to newborns of HBSaG positive mothers |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Risk categories | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y11-Y14 | HPV administered to females and males | Females and Males from 2023 (If the vaccine is given over 15 years of age, 3 doses must be given) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Females and Males from 2023 (If the vaccine is given over 15 years of age, 3 doses must be given) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Travellers | Travellers | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | Travellers | Travellers (given in Italy) | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M13 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Risk categories, travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Travellers | Risk categories, travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y13 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | M4 | General/routine | |
| MEN_BMeningococcal B vaccine | 2 | M6 | General/routine | |
| MEN_BMeningococcal B vaccine | 3 | M13 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M15 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y6 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M3 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | Risk categories | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M5 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M11 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | Risk categories | |
| RABIESRabies vaccine | 1 | Risk group(s) | Risk categories | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | Risk group(s) | Risk categories | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant women | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | General/routine | Newborns | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y25 | Adults | Adults every 10 years |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 2 | +Y10 | Adults | Adults every 10 years |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 3 | +Y10 | Adults | Adults every 10 years |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 4 | +Y10 | Adults | Adults every 10 years |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | +Y10 | Adults | Adults every 10 years |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | +Y10 | Adults | Adults every 10 years |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 5 | Y15 | General/routine | |
| TTTT (Tetanus toxoid) vaccine | 1 | Y25 | Adults | Every 10 years to individuals that refuse TdaP |
| TTTT (Tetanus toxoid) vaccine | 2 | +Y10 | Adults | Every 10 years to individuals that refuse TdaP |
| TTTT (Tetanus toxoid) vaccine | 3 | +Y10 | Adults | Every 10 years to individuals that refuse TdaP |
| TTTT (Tetanus toxoid) vaccine | 4 | +Y10 | Adults | Every 10 years to individuals that refuse TdaP |
| TTTT (Tetanus toxoid) vaccine | 5 | +Y10 | Adults | Every 10 years to individuals that refuse TdaP |
| TTTT (Tetanus toxoid) vaccine | 6 | +Y10 | Adults | Every 10 years to individuals that refuse TdaP |
| TYPHOID_CONJTyphoid conjugate vaccine | 1 | Travellers | Travellers | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers | Travellers | |
| VARICELLAVaricella vaccine | 1 | M15 | General/routine | Since 2023, the varicella vaccine has been administered mandatorily together with the measles vaccine. |
| VARICELLAVaricella vaccine | 2 | Y6 | General/routine | Since 2023, the varicella vaccine has been administered mandatorily together with the measles vaccine. |
| YFYF (Yellow fever) vaccine | 1 | Travellers | Travellers (given in Italy) | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Risk group(s) | Risk categories |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.